Abbott India inches up on inking pact with Novo Nordisk India to launch Extensior
Abbott India is currently trading at Rs. 26598.50, up by 103.35 points or 0.39% from its previous closing of Rs. 26495.15 on the BSE.
The scrip opened at Rs. 26000.00 and has touched a high and low of Rs. 26673.10 and Rs. 26000.00 respectively. So far 51 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 35921.55 on 03-Jul-2025 and a 52 week low of Rs. 26,000.00 on 2-Mar-2026.
Last one week high and low of the scrip stood at Rs. 26673.10 and Rs. 26000.00 respectively. The current market cap of the company is Rs. 55949.41 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 9.18% and 15.83% respectively.
Abbott India has entered into strategic collaboration with Novo Nordisk India to commercialize Extensior for people living with type 2 diabetes. This partnership leverages Novo Nordisk’s scientific leadership in GLP-1s and Abbott’s strong distribution network to expand access in India to a high-quality, evidence-based diabetes therapy, beyond regions Novo Nordisk currently serves. Extensior is a second brand of Ozempic, the world’s most prescribed GLP-1 RA (receptor agonist) molecule.
Extensior is approved as an adjunct to diet and exercise for adults with type 2 diabetes and is a GLP-1 RA recognized for offering the broadest range of benefits for people with this condition. Semaglutide, the molecule in Extensior, has demonstrated powerful HbA1c reduction, compelling weight-loss benefits, and proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes.
